Back كونفيديسيا Arabic Convidecia Catalan Convidecia Czech Convidecia Spanish کانسینو Persian Ad5-nCoV French Convidecia ID Convidecia Italian Ad5-nCoV Japanese 칸시노 코로나19 백신 Korean
 A multi-dose vial of Convidecia (AD5-nCOV) filled and finished in Mexico | |
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Trade names | Convidecia |
| Other names | PakVac |
| Routes of administration | Intramuscular, Nebulizer |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
AD5-nCOV, trade-named Convidecia, is a single-dose[2] viral vector vaccine for COVID-19 that is also used as an inhaled booster. It was developed by CanSino Biologics, with Phase III trials conducted in Argentina,[3] Chile,[4] Mexico,[5] Pakistan,[6] Russia,[7] and Saudi Arabia[8] with 40,000 participants.
In February 2021, global data from Phase III trials and 101 COVID cases showed that the intramuscular version of the vaccine had a 65.7% efficacy in preventing moderate symptoms of COVID-19, and 91% efficacy in preventing severe disease.[9] It has similar efficacy to the Janssen vaccine, another one-shot adenovirus vector vaccine with 66% efficacy in a global trial.[10][2] Convidecia is similar to other viral vector vaccines like AZD1222, Gam-COVID-Vac, and Ad26.COV2.S.[11] Its single-dose regimen and normal refrigerator storage requirement (2° to 8 °C) could make it a favorable vaccine option for many countries.[10] It is currently under evaluation for emergency use listing by the WHO.[12] On May 19 2022, WHO issued EUL for the vaccine.[13]
A Phase I study published in The Lancet showed two doses of a nebulised version of Convidecia (inhaled through the mouth) resulted in neutralising antibody responses similar to the existing one-dose injection.[14]
Convidecia and the Pakistani version called PakVac are approved for use by some countries in Asia,[15][16][17] Europe,[18][19] and Latin America.[20][21][22] Production capacity for Ad5-NCov should reach 500 million doses in 2021. Manufacturing will take place in China,[23] with filling and finishing of the vaccine additionally also taking place in Malaysia,[17] Mexico,[24] and Pakistan.[25]
- ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ^ a b "It's not just Johnson & Johnson: China has a single-dose COVID-19 vaccine that has 65% efficacy". Fortune. Retrieved 2021-02-11.
- ^ Cite error: The named reference
:0was invoked but never defined (see the help page). - ^ Cite error: The named reference
:9was invoked but never defined (see the help page). - ^ Cite error: The named reference
:10was invoked but never defined (see the help page). - ^ Cite error: The named reference
NCT04526990was invoked but never defined (see the help page). - ^ Cite error: The named reference
:11was invoked but never defined (see the help page). - ^ Cite error: The named reference
:12was invoked but never defined (see the help page). - ^ "CanSinoBIO's COVID-19 vaccine 65.7% effective in global trials, Pakistan official says". Reuters. 8 February 2021. Retrieved 2021-02-08.
- ^ a b "China's CanSino Covid Vaccine Shows 65.7% Efficacy". Bloomberg.com. 2021-02-08. Retrieved 2021-02-10.
- ^ Zimmer C, Corum J, Wee SL (2020-06-10). "Coronavirus Vaccine Tracker". The New York Times. ISSN 0362-4331. Retrieved 2020-12-12.
- ^ "Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process" (PDF). World Health Organization. 15 July 2021. Archived (PDF) from the original on 2021-07-16.
- ^ "WHO Validates 11th Vaccine for COVID-19". World Health Organization. 19 May 2022.
- ^ Wu S, Huang J, Zhang Z, Wu J, Zhang J, Hu H, et al. (July 2021). "Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial". The Lancet. Infectious Diseases. 21 (12): 1654–1664. doi:10.1016/S1473-3099(21)00396-0. PMC 8313090. PMID 34324836.
- ^ Cite error: The named reference
:13was invoked but never defined (see the help page). - ^ Cite error: The named reference
arynews.tvwas invoked but never defined (see the help page). - ^ a b Cite error: The named reference
:3was invoked but never defined (see the help page). - ^ Cite error: The named reference
Ashokwas invoked but never defined (see the help page). - ^ "Membrii NITAG au venit cu recomandări privind utilizarea vaccinurilor împotriva COVID-19 în Republica Moldova". Ministerul Sănătății, Muncii și Protecţiei Sociale. 2021-03-03. Retrieved 2021-05-21.
- ^ Cite error: The named reference
:17was invoked but never defined (see the help page). - ^ "Argentina issues emergency approval to China's single-dose Cansino COVID-19 vaccine". Reuters. 2021-06-11. Retrieved 2021-06-11.
- ^ "ISP Approves Emergency Use And Importation Of Cansino Vaccine To Fight COVID-19". Institute of Public Health of Chile. Archived from the original on 2021-04-07. Retrieved 2021-04-08.
- ^ "China can hit 500-mln-dose annual capacity of CanSinoBIO COVID-19 vaccine this year". finance.yahoo.com. 27 February 2021. Archived from the original on 2021-02-27. Retrieved 2021-02-28.
- ^ Cite error: The named reference
:6was invoked but never defined (see the help page). - ^ "Pakistan develops homemade anti-Covid vaccine 'PakVac'". The Express Tribune. 2021-05-24. Retrieved 2021-05-25.